Genfit S.A.: Ipsen Makes a Milestone Payment of €26.5 Million Under the Licensing and Cooperation Agreement!

Genfit S.A. (i.) is a French biotechnology company that specializes in the development of innovative therapies for liver diseases. It particularly focuses on rare, difficult-to-treat conditions such as acute-on-chronic liver failure (ACLF) and primary biliary cholangitis (PBC). For investors, Genfit is a potentially interesting but also risky stock in the biotechnology sector. On May 21, the biotech announced that Iqirvo from Ipsen has received price and reimbursement approval in Italy for the treatment of primary biliary cholangitis (PBC)....